First Tracks Biotherapeutics, Inc. (TRAX) News
Track canonical SquawkNews coverage tagged to TRAX, First Tracks Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
First Tracks Biotherap Initiated at Buy by Canaccord Genuity
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 11:47 AM UTC
L
TRAX: Advancing dual-mechanism CD122 therapy in celiac and EoE, with key data and expansion ahead
The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expect
EQUITY | Sep 09, 2026, 03:26 PM UTC
L
TRAX advances CD122 antibody for celiac and EoE; phase I-B soon
TRAX, newly formed from a spinout, is developing a dual-mechanism CD122 antibody for celiac disease and EoE. Phase I-B data are expected soon, with plans to expand into additional indications.
EQUITY | Sep 09, 2026, 02:38 PM UTC
L
TRAX director sells common shares worth $1,758,145
Director Ware J. Anthony reported selling common stock on 2026-09-02 at a weighted average price of $44.7764 per share, for $1,758,145 total.
EQUITY | Sep 04, 2026, 08:31 PM UTC
L
First Tracks Biotherap price target held at $57.00
HC Wainwright & Co. maintained a $57.00-per-share price target for First Tracks Biotherap, according to TradingView News via Benzinga.
EQUITY | Sep 03, 2026, 11:54 AM UTC
L
First Tracks Biotherapeutics to participate in September investor conferences
First Tracks Biotherapeutics announced it will participate in September investor conferences.
EQUITY | Aug 26, 2026, 08:17 PM UTC
L
TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences
TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences
EQUITY | Aug 26, 2026, 08:15 PM UTC
L
TRAX Announces Q2 2026 Financial Results
TRAX announces second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 08:16 PM UTC
L
First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why
First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why
EQUITY | Jul 21, 2026, 10:20 AM UTC